Trial Profile

An Open-label, Multicenter, Phase Ib/III Study of Efficacy and Safety of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jun 2023 Results of pooled analysis of two studies (NCT05005234 & NCT05497336) assessing efficacy and safety of IBI351 monotherapy for metastatic colorectal cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
06 Jun 2023 Interim results presented in an Innovent Biologics media release.
06 Jun 2023 According to an Innovent Biologics media release, Interim results pooled from two Phase 1 studies (NCT05005234, NCT05497336), presented at at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com